Biotech Healthcare launches Optiflex XTENSE Comfort Plus EDOF IOL

The Optiflex lens can be used in correction of both cataracts and presbyopia. Image credit: Starry sky: Nikiko from pixabay. IOL: Ogtay Mammadov from Getty Images.

Biotech Healthcare announced the European launch of its new extended depth-of-field (EDOF) IOL.¹ The company debuted the new technology, as well as information about its performance, at the 2025 European Society of Cataract and Refractive Surgeons (ESCRS) Congress. During the congress, multiple clinicians shared their surgical experiences with the new Optiflex XTENSE Comfort Plus lens, including Prof Claudette Abela-Formanek, head of the specialty clinic for cataract surgery at Medical University of Vienna, Austria; Dr Altan Ozcan, professor of ophthalmology at Cukurova University School of Medicine in Adana, Türkiye; Prof Sri Ganesh, chairman and managing director at Nethradhama Hospitals Pvt Ltd, Bangalore, India; and Dr D. Ramamurthy, chairman of The Eye Foundation, with 10 tertiary care eye hospitals throughout India.¹

According to the press release, Dr Ozcan said that the lens offered “very good near distance and intermediate vision,” without dysphotopsia or other visual disturbances. “Patients are enjoying sharp near and intermediate vision,” Biotech Healthcare reports Dr Ozcan as saying. Meanwhile, surgical outcomes reported by Prof Abela-Formanek, Prof Ganesh and Dr Ramamurthy support the stated design goals of the lens, offering “a purely refractive optical profile that avoids diffractive rings, delivering high-definition vision across near, intermediate, and distance without compromise,” per the press release.¹

The Optiflex lens can be used for both cataract and presbyopia correction, to minimise visual side effects and improve visual comfort. A company representative stated that the lens received an “enthusiastic response” from clinicians during the ESCRS Congress.

A product page on the Biotech Healthcare website shares technical specifications of the Optiflex XTENSE Comfort Plus.² In an assessment of 30 patients implanted with the lens, 89.66% of patients exhibited uncorrected distance visual acuity of 0.0 logMAR or better. Additionally, 68.97% of subjects exhibited uncorrected Intermediate visual acuity of 0.0 logMAR or better, while 86.2% of subjects exhibited uncorrected visual acuity of 0.1 logMAR or better. At a 3-month postoperative follow up, patients' binocular defocus demonstrated an improved extended range of vision > 3.0 D at 0.2 Log MAR or better.²

Biotech Healthcare operates within ophthalmology, dermatology and orthopaedics. The company’s products are available in more than 110 countries.³ Founded in India, the company is headquartered jointly in Luzern, Switzerland (sales and marketing), Roscommon, Ireland and Ahmedabad, India (research & development and manufacturing centres).

References:

1. Biotech Healthcare Announces the Successful Launch of Optiflex XTENSE Comfort Plus (Full Visual Range EDOF IOL) at ESCRS 2025, Copenhagen. Press release. Biotech Healthcare. Published October 6, 2025. Accessed October 14, 2025.

2. Optiflex XTENSE Comfort Plus full visual range of EDOF IOL features. Biotech Healthcare. Accessed October 14, 2025. https://biotechhealthcare.com/products/optiflex-xtense-comfort-plus/

3. About Us. Biotech Healthcare. Accessed October 14, 2025. https://biotechhealthcare.com/about-us/